news

<body bgcolor="#eeeeee"> <table width="500" border="0" cellspacing="0" cellpadding="0"> <tr> <td width="100"><a href="pressrel/pressrel.html">press releases</a></td> <td width="100"><a href="publicat/public.html">publications</a></td> <td width="100"><a href="events/event.html">events</a></td> <td width="100"><a href="jobcaree/jobcaree.html">jobs careers</a></td> <td width="100"><a href="../index.html">home</a></td> </tr> <tr> <td colspan="5" width="500">German-Sino Biotechnology co-operation Bicoll to complete first year in Shanghai successfully<br> Bicoll Biotechnology (Shanghai) Co. Ltd., a 100% subsidiary of Bicoll GmbH, Germany, has successfully completed the Chinese company's build-up process in Shanghai / P.R. China within one year only. The general manager of Bicoll Biotechnology (Shanghai) Co. Ltd., Dr. Kai Lamottke, is highly satisfied about the prompt implementation of the company's proprietary technology platform. First products have already been launched into exclusive co-operations and partnerships. Within the next three years, Bicoll Biotechnology (Shanghai) Co. Ltd. is planning to extend the company's research and development location from up to date 10 employees to over 50.<br> The Bicoll group is an internationally orientated biopharmaceutical enterprise with a headquarters office in Munich, Germany, and its research and development location in Shanghai, P.R. China.<br> The company provides an innovative, fast and flexible approach to modern drug research. Bicoll's competence stretches from natural product chemistry to combinatorial chemistry, screening techniques, structural biology, own developed novel deconvolution technology, isolation strategies and structural elucidation.<br> Bicoll provides optimized, high-quality small molecule libraries (BILOBAC N) for drug discovery co-operations with companies of the biopharmaceutical industry. The submitted libraries are specially designed for the target protein of the partner's indication field to provide highest success rate. The starting material is generated through Bicoll's access to Asian plant resources.<br> Bicoll's two core technologies BIFRAC N and BIPRESELECT enable the company to accelerate the development process of new drug candidates. BIFRAC N is an isolation and separation system to detect biologically active compounds. By applying the BIPRESELECT process, the company identifies selected ADME criteria. Thus Bicoll is able to sort out non-successful drug candidates, which would otherwise block the drug development pipeline. Bicoll's technology shortens the time-consuming and expensive process of lead discovery and pre-clinical studies by around one third.<br> Currently, Bicoll is initiating its own in-house drug development projects, one of which is in the area of central nervous system disorders. </td> </tr> <tr> <td width="100"><a href="../a_bicoll/fr_about.html">about bicoll</a></td> <td width="100"><a href="fr_news.html">news</a></td> <td width="100"><a href="../research/fr_resea.html">research</a></td> <td width="100"><a href="../business/fr_busin.html">business</a></td> <td width="100"><a href="../contact/fr_cont.html">contact</a></td> </tr> </table> </body>